Advancements in Parkinson disease treatments and neuro therapies

Recent developments in Parkinson's disease treatment include the FDA clearance of the Cala kIQ Plus, a next-generation wearable neurostimulation device for tremor management, announced in mid-April 2026. Additionally, new clinical data presented at the American Academy of Neurology (AAN) annual meeting (April 18-22, 2026) highlighted sustained benefits of the investigational cell therapy bemdaneprocel, positive results for the experimental oral drug tavapadon, and promising proof-of-concept findings for non-invasive focused ultrasound as a potential alternative to deep brain stimulation.

• FDA Clearance: Cala kIQ Plus: The FDA cleared the Cala kIQ Plus, a wearable neurostimulation device for temporary relief of hand tremors in Parkinson's disease, announced on April 15, 2026. 📅 Calendar file (.ics) FDA clearance of Cala kIQ Plus April 15, 2026
• AAN 2026 Conference: The American Academy of Neurology (AAN) annual meeting was held in Chicago and online, featuring several key updates on Parkinson's research. (April 18, 2026 – April 22, 2026) 📅 Calendar file (.ics) American Academy of Neurology (AAN) Annual Meeting April 18, 2026 – April 22, 2026